A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC
Status:
Terminated
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
Primary Objective for Phase I
1. To determine the maximally tolerated dose (MTD) of daily Oral dasatinib in combination
with cetuximab/RT in Cohort A.
2. To determine the MTD of daily oral dasatinib in combination with cisplatin/cetuximab/RT
in Cohort B
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins